A retrospective study of 229 patients with rifampicin-resistant or multidrug-resistant tuberculosis found that ...
A retrospective study of 606 clinically referred people in northeastern Mexico characterized two-field HLA allele and ...
7don MSN
Verastem Oncology's investigational drug delivers encouraging responses across multiple cancers
Verastem Oncology VSTM reported encouraging early clinical results for its experimental KRAS G12D inhibitor VS-7375, with the ...
When the body treats a therapeutic antibody as foreign, it produces anti-drug antibodies that can blunt the drug’s effect, change how it moves through the body and raise safety concerns. The FDA’s ...
Clinical Trials Arena on MSN
Verastem’s KRAS inhibitor posts wins in mPDAC, mCRC and NSCLC
Verastem is advancing the KRAS inhibitor into later stage studies following the data readout.
When researching cancer genetic testing, you may come across the term 'FFPE'.This is a specimen commonly used in pathology testing, but it is likely not very familiar to the general public.In cancer ...
Verastem (NASDAQ:VSTM) presented updated clinical data for VS-7375, an oral, highly selective KRAS G12D inhibitor, from its ...
Vitamin C is a powerful epigenetic drug, which is not generally realized,” said Peter A. Jones, PhD, DSc (hon). Patients with ...
Questions that remain after being told you are 'low risk'When told, 'Your disease is low risk,' most people first feel a ...
TP53 mutations occurred in 3% of myeloproliferative neoplasms (MPNs) but 10% of myelofibrosis or blast-phase cohorts in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results